Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 341 de 371.

Grafa
Health

Alcon scraps $1.6B STAAR Surgical deal after shareholder revolt

Alcon (NYSE:ALC), the global leader in eye care, officially terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) on Tuesday, January 6, 2026.

The collapse of the deal, originally valued at $1.5 billion and later raised to approximately $1.6 billion, follows a decisive rejection by STAAR’s stockholders at a special meeting earlier that day.

Leia mais: Alcon scraps $1.6B STAAR Surgical deal after shareholder revolt
Grafa

Franklin Resources hits $1.68 trillion in assets as retail inflows counter fixed-income headwinds

Franklin Resources (NYSE:BEN), the global investment giant operating as Franklin Templeton, reported a slight uptick in preliminary assets under management (AUM) to $1.68 trillion as of December 31, 2025.

The results cap a complex quarter defined by robust organic growth in equity and alternatives, even as its Western Asset Management unit continued to grapple with institutional fixed-income outflows.

Leia mais: Franklin Resources hits $1.68 trillion in assets as retail inflows counter fixed-income headwinds
Grafa
Technology

HIVE Digital surges as 2025 Bitcoin production jumps 31%

HIVE Digital Technologies (NASDAQ:HIVE) shares traded higher on Wednesday, January 7, 2026, following the release of its December 2025 production report and full-year results.

The company reported a banner year, producing 2,311 BTC in 2025—a 31% increase over the previous year—despite the significant headwinds of the 2024 halving and a 46% year-over-year surge in average network difficulty.

Leia mais: HIVE Digital surges as 2025 Bitcoin production jumps 31%
Grafa
Health

GSK and Ionis break new ground in Hepatitis B with positive Phase 3 results

Ionis Pharmaceuticals (NASDAQ:IONS) shares hovered near 52-week highs Wednesday after partner GSK (NYSE:GSK) announced that its experimental drug, bepirovirsen, successfully met the primary endpoints in two pivotal Phase 3 trials, B-Well 1 and B-Well 2.

Leia mais: GSK and Ionis break new ground in Hepatitis B with positive Phase 3 results